FGFR2 N549H

CI-VAR-00002918Explore in graph →CIViC 2780

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive2
FGFR2 N549H	Bosutinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID7510 In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to bosutinib treatment at concentrations of 1μM and 10μM (activity %: 32 and 3) when compared to wild ty… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC	civic
FGFR2 N549H	Dasatinib	Predictive	D	Supports Sensitivity Response	2	submitted	EID7511 In an in vitro kinase study, the recombinant FGFR2 N549H mutant kinase demonstrated sensitivity to dasatinib treatment at concentrations of 1μM and 10μM (activity %: 6 and -1) when compared to wild ty… (full text at CIViC) PMID 19039322 · Remsing Rix et al., 2009 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.